Loading
Transplant rejection — acute vs chronic, the warning signs patients can catch, how biopsy decides treatment, and why most rejection is treatable.
Evidence reviewed & updated: 2026-08 — reflects the latest published trials and guidelines.
Rejection is the immune system attacking the new kidney — and it's far more treatable than patients fear: acute rejection responds to treatment in the large majority of cases, especially caught early. The patient's job is knowing the signs (fever, reduced urine, weight gain, tenderness) and the daily medication discipline; the team's job is surveillance, biopsy, and targeted therapy.
Acute rejection: the immune system attacks the graft over days-weeks — most commonly in the first year, when surveillance is densest. It's usually cellular (T-cells) but can be antibody-mediated (donor-specific antibodies attacking vessels) — the more aggressive form.
Chronic rejection: slow, progressive graft damage over months-years, often from a mix of antibody injury, calcineurin toxicity, and recurrent disease. It's managed, not 'reversed' — with medication optimization and preparation for re-transplant if needed.
Patient-watchable: fever, reduced urine, sudden weight gain, swelling or tenderness over the graft. Lab-watchable: creatinine rising — which is why the clinic rhythm of blood draws is the real early-warning system, catching rejection before symptoms.
Biopsy is the definitive step: a needle sample distinguishes cellular rejection (steroid-treatable), antibody-mediated rejection (plasmapheresis + IVIG + antibody-targeting drugs), and non-immune causes (calcineurin toxicity, recurrent disease, infection).
Cellular rejection: pulse intravenous steroids — most cases respond, often with full recovery of function. Antibody-mediated: plasmapheresis to strip antibodies, IVIG, and agents like rituximab or eculizumab — more intensive, but effective when started early.
Prevention is the patient's medicine: the daily pill habit is the single largest lever — non-adherence is the leading preventable cause of graft loss — plus BP and glucose control, and never stopping immunosuppression without the team's say-so.
The first year after transplant is the most intensive — clinic visits weekly-to-monthly, a strict medication routine, an...
Learn moreImmunosuppression is the price of transplant: a lifelong regimen that keeps the immune system from killing the new kidne...
Learn moreFor most patients with kidney failure, transplant beats dialysis on survival, quality of life, and long-term cost — pati...
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement